Literature DB >> 28515939

Vaccine against arteriosclerosis: an update.

Kuang-Yuh Chyu1, Paul C Dimayuga1, Prediman K Shah2.   

Abstract

Substantial data from experimental and clinical investigation support the role of immune-mediated mechanisms in atherogenesis, with immune systems responding to many endogenous and exogenous antigens that play either proatherogenic or atheroprotective roles. An active immunization strategy against many of these antigens could potentially alter the natural history of atherosclerosis. This review mainly focuses on the important studies on the search for antigens that have been tested in vaccine formulations to reduce atherosclerosis in preclinical models. It will also address the opportunities and challenges associated with potential clinical application of this novel therapeutic paradigm.

Entities:  

Keywords:  apolipoprotein B-100; atherosclerosis; immunization; low-density lipoprotein

Year:  2017        PMID: 28515939      PMCID: PMC5418889          DOI: 10.1177/2051013617693753

Source DB:  PubMed          Journal:  Ther Adv Vaccines        ISSN: 2051-0136


  71 in total

1.  Phosphorylcholine-targeting immunization reduces atherosclerosis.

Authors:  Giuseppina Caligiuri; Jamila Khallou-Laschet; Marta Vandaele; Anh-Thu Gaston; Sandrine Delignat; Chantal Mandet; Heinz V Kohler; Srini V Kaveri; Antonino Nicoletti
Journal:  J Am Coll Cardiol       Date:  2007-07-23       Impact factor: 24.094

2.  Anti-atherogenic peptide Ep1.B derived from apolipoprotein E induces tolerogenic plasmacytoid dendritic cells.

Authors:  S M Bellemore; E Nikoopour; B C Y Au; O Krougly; E Lee-Chan; S M Haeryfar; B Singh
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

3.  Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis.

Authors:  C W Rittershaus; D P Miller; L J Thomas; M D Picard; C M Honan; C D Emmett; C L Pettey; H Adari; R A Hammond; D T Beattie; A D Callow; H C Marsh; U S Ryan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-09       Impact factor: 8.311

4.  Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65.

Authors:  Q Xu; H Dietrich; H J Steiner; A M Gown; B Schoel; G Mikuz; S H Kaufmann; G Wick
Journal:  Arterioscler Thromb       Date:  1992-07

5.  LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis.

Authors:  X Zhou; G Caligiuri; A Hamsten; A K Lefvert; G K Hansson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-01       Impact factor: 8.311

Review 6.  The role of T and B cells in human atherosclerosis and atherothrombosis.

Authors:  E Ammirati; F Moroni; M Magnoni; P G Camici
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

7.  Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences.

Authors:  Gunilla Nordin Fredrikson; Ingrid Söderberg; Marie Lindholm; Paul Dimayuga; Kuang-Yuh Chyu; Prediman K Shah; Jan Nilsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-20       Impact factor: 8.311

8.  Mycobacterial heat shock protein 65 (mbHSP65)-induced atherosclerosis: Preventive oral tolerization and definition of atheroprotective and atherogenic mbHSP65 peptides.

Authors:  Cecilia Grundtman; Bojana Jakic; Maja Buszko; Elisabeth Onestingel; Giovanni Almanzar; Egon Demetz; Hermann Dietrich; Giuseppe Cappellano; Georg Wick
Journal:  Atherosclerosis       Date:  2015-06-30       Impact factor: 5.162

9.  Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.

Authors:  Gergana Galabova; Sylvia Brunner; Gabriele Winsauer; Claudia Juno; Bettina Wanko; Andreas Mairhofer; Petra Lührs; Achim Schneeberger; Arne von Bonin; Frank Mattner; Walter Schmidt; Guenther Staffler
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

10.  Autoreactive HSP60 epitope-specific T-cells in early human atherosclerotic lesions.

Authors:  Giovanni Almanzar; Robert Öllinger; Julianna Leuenberger; Elisabeth Onestingel; Barbara Rantner; Sarah Zehm; Benno Cardini; Ruurd van der Zee; Cecilia Grundtman; Georg Wick
Journal:  J Autoimmun       Date:  2012-08-15       Impact factor: 7.094

View more
  8 in total

1.  The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1β and vascular inflammation.

Authors:  Valmore Bermúdez; Joselyn Rojas-Quintero; Manuel Velasco
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 2.  Novel Antiatherosclerotic Therapies.

Authors:  Peter Libby; Brendan M Everett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

3.  Retinoic Acid-Loaded Poly(lactic-co-glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis.

Authors:  Xianwen Yi; Ying Wang; Zhenquan Jia; Sylvia Hiller; Jun Nakamura; J Christopher Luft; Shaomin Tian; Joseph M DeSimone
Journal:  J Biomed Nanotechnol       Date:  2020-04-01       Impact factor: 4.099

4.  Serum Anti-Apo B Antibody Level as Residual CVD Marker in DM Patients under Statin Treatment.

Authors:  Hiroyasu Yamamoto; Mari Kawamura; Ikoi Kochi; Minami Imai; Yukie Murata; Toshinobu Suzuki; Yingchao Chen; Kunihiko Hashimoto; Shinji Kihara
Journal:  J Atheroscler Thromb       Date:  2019-03-14       Impact factor: 4.928

5.  Reducing the Damage of Ox-LDL/LOX-1 Pathway to Vascular Endothelial Barrier Can Inhibit Atherosclerosis.

Authors:  Xiaopeng Guo; Yishan Guo; Zhiwen Wang; Bingxin Cao; Chuansheng Zheng; Zhuanglin Zeng; Yumiao Wei
Journal:  Oxid Med Cell Longev       Date:  2022-03-29       Impact factor: 6.543

Review 6.  Vaccination against Atherosclerosis: Is It Real?

Authors:  Anastasia V Poznyak; Evgeny E Bezsonov; Tatyana V Popkova; Antonina V Starodubova; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

Review 7.  Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis.

Authors:  Kongye Lu; Benli Su; Xiuxiang Meng
Journal:  J Diabetes Res       Date:  2018-09-24       Impact factor: 4.011

8.  Intein mediated high throughput screening for bispecific antibodies.

Authors:  Tim Hofmann; Johannes Schmidt; Elke Ciesielski; Stefan Becker; Thomas Rysiok; Mark Schütte; Lars Toleikis; Harald Kolmar; Achim Doerner
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.